'Immunexcite'[s] investors, pads coffers with $8.6M A-1 round
By Marie Powers
Staff Writer
Staff Writer
Thursday, March 31, 2016
Immunexcite Inc. completed an $8.6 million series A-1 financing, topping off a series of smaller rounds that sustained the immuno-oncology (I-O) company and its technology, dubbed Mabxcite, for more than five years. All told, the Lexington, Mass.-based company has raised more than $15 million since it was incorporated in 2007, mostly beginning with a $2.4 million series A at the end of 2011.
To continue reading subscribe now to Latest News
Learn More about Latest News
Already a subscriber? Sign In or Buy now to activate your subscription
Note: our contact information has changed
Customer Care: http://support.clarivate.com
© 2018 Clarivate Analytics.
Reproduction, reposting content is strictly prohibited.
Reproduction, reposting content is strictly prohibited.